Steve Glover
Co-founder, Chairman and Chief Executive Officer @Zyversa Therapeutics Inc
Signup · Get unlimited contacts
WORK HISTORY
Co-founder, Chairman and Chief Executive Officer @Zyversa Therapeutics Inc
ZyVersa is a clinical stage specialty biopharmaceutical company leveraging advanced proprietary technologies to develop first-in-class drugs. Our focus is on patients with inflammatory or renal diseases who have high unmet medical needs. Our clinical pipeline includes phase 2a-ready VAR 200, a cholesterol efflux mediator for treatment of an orphan renal disease, focal segmental glomerulosclerosis (FSGS), and a novel inflammasome inhibitor with potential for multiple inflammatory diseases.Our accomplished leadership team has demonstrated success across all disciplines in the biopharmaceutical industry. A key focus is assuring that our development efforts serve the needs of all our stakeholders: patients, health care providers, payors, and our investors.Our evolving product pipeline is targeted to the $60+ billion anti-inflammatory market and the $13+ billion renal drug market. Our lead renal drug candidate is 2-hydroxypropyl-beta-cyclodextrin (2HPβCD), a cholesterol efflux mediator demonstrated in preclinical studies to promote cholesterol removal from podocytes, the kidney\'s filtering system, slowing progression of podocyte injury and renal disease. Our lead anti-inflammatory drug candidate is a novel inflammasome inhibitor targeting the upstream innate immune system. It inhibits the ASC component of inflammasomes, blocking intracellular initiation of the inflammatory cascade and extracellular perpetuation of inflammation.
SKILLS
ABOUT STEVE GLOVER
Mr. Glover has over 35+ years of business experience in biopharmaceuticals and life sciences. Currently Mr. Glover is Co-Founder, Chairman, President and CEO of ZyVersa Therapeutics. Before founding ZyVersa, Mr. Glover was Co-Founder and CBO of Coherus Biosciences where he was focused on the business strategy, partnerships, product development efforts and capitalization of the company. Prior to Coherus, he was the President of Insmed Therapeutic Proteins, a biosimilar company, as well as Chief Business Officer of Insmed Incorporated.Prior to Insmed, Mr. Glover held the position of Senior Vice President and General Manager at Andrx Laboratories and Andrx Therapeutics, both divisions of Andrx Corporation. At Andrx Mr. Glover was responsible for the strategy and operation of Andrx Labs which developed and marketed products in metabolic diseases and Men\'s Health and Andrx Therapeutics which was focused on the development of new controlled release products and contract manufacturing. He earlier held multiple sales, marketing and operational roles at GSK, Hoffman LaRoche, Amgen Inc. and IMS Health. Mr. Glover has multifaceted experience in Fortune 100, start up and entrepreneurial environments. He has demonstrated results in start ups, large cap and turnarounds with a focus on business strategy, commercial execution, product development, business transformation and corporate development. He has over 25 life sciences transactions in licensing and M&A and has raised over $500M in capital. His strategic and operational experience includes strategic planning, corporate development, operations management, product development, product marketing and sales management.Currently Mr. Glover serves on the Board of Directors of ZyVersa Therapeutics, Chairman of the BOD at PDS Biotechnology, Director at Biogene Therapeutics, Former Chairman of the BOD at Ambrx and is a BOD Member The Coulter Foundation at the University of Miami.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.